Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 6 HBV multivariate adjusted OR

From: Demographic, risk behaviour and personal network variables associated with prevalent hepatitis C, hepatitis B, and HIV infection in injection drug users in Winnipeg, Canada

Variable name OR (95% CI) p value
Years of injection drug use
Categories based on quartiles (Q1–Q4 below)
  
Q2 vs. Q1 4.7 (1.6–13.9) 0.005
Q3 vs. Q1 11.3 (3.8–33.2) <0.001
Q4 vs. Q1 15.7 (5.3–46.5) <0.001
Ever used someone else's used syringe   
Yes vs. No 2.2 (1.2–4.0) 0.005
injected at a shooting gallery   
Yes vs. no 2.9 (1.3–6.3) 0.020
Opposite-sex casual sex partners   
Yes vs No 0.5 (0.3–0.9) 0.020
Mobility (Moved to Winnipeg in past year)   
Yes vs. no 0.3 (0.2–0.7) 0.004
Number of IDU in network who use talwin/ritalin   
1–3 vs. none 2.9 (1.4–5.9) <0.005
4–5 vs none 3.2 (1.4–7.2) <0.009
Number of IDU in network who have intiated respondent to injection drug use   
1 vs. none 0.6 (0.3–1.4) 0.248
2–5 vs. none 0.1 (0.02–0.8) 0.023
Number of IDU in risk network who have injected at a hotel   
1 vs. none 1.3 (0.6–2.6) 0.490
2–5 vs. none 2.8 (1.3–5.9) 0.006